Antidepressant mechanisms of a food-medicine homologous compound concentrate from Hemerocallis citrina Baroni: Regulation of PI3K/AKT/BDNF signaling pathway in preclinical models

Abstract

Objective: To determine the optimal dosing ratio of the herbal components within compound Hemerocallis citrina Baroni (H. citrina) extract concentrate (CHEC), evaluate its antidepressant effects in zebrafish and mouse models of depression, and elucidate the underlying mechanisms with a particular focus on the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/brain-derived neurotrophic factor (BDNF) signaling pathway using network pharmacology and molecular biology approaches.

Methods: The optimal CHEC formulation was screened using a zebrafish model of reserpine-induced depression. To assess neuroinflammation and monoamine neurotransmitter levels, the levels of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, dopamine, and 5-hydroxytryptamine in zebrafish brain tissues were measured using enzyme-linked immunosorbent assay kits. Active constituents were identified by liquid chromatography-tandem mass spectrometry and potential targets were predicted using the Swiss Target Prediction database. A traditional Chinese medicine–active ingredient–target network and a protein–protein interaction network were constructed, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses to explore potential mechanisms. A mouse model of depression was subsequently established using chronic restraint stress (CRS) combined with intraperitoneal lipopolysaccharide injection. The antidepressant effects of CHEC were assessed through behavioral tests, quantification of monoamine neurotransmitters and inflammatory cytokines, histopathological examination of hippocampal neurons using hematoxylin and eosin staining, and Western blot analysis of PI3K/AKT/BDNF pathway-related proteins.

Results: CHEC significantly alleviated depressive-like behaviors in CRS mice, as demonstrated by behavioral assessments. Treatment reduced levels of pro-inflammatory cytokines and restored monoamine neurotransmitter concentrations. Histological analysis revealed attenuation of hippocampal neuronal damage. Furthermore, CHEC significantly modulated the PI3K/AKT/BDNF signaling pathway in the hippocampus of depressive-like mice.

Conclusion: CHEC exerts antidepressant-like effects by suppressing inflammatory cytokines, including tumor necrosis factor-alpha, IL-6, and IL-1β; enhancing dopamine and BDNF levels; and regulating the PI3K/AKT/BDNF signaling pathway. These findings provide mechanistic evidence supporting the therapeutic potential of CHEC for depression.

Keywords

Hemerocallis citrina Baroni / Depression / Network pharmacology / PI3K/AKT/BDNF

Funding

This study was financially supported by the National Key R&D Program of China (2024YFD1600800) and the Key Research and Development Program of Ningxia (2024BEG01006).

CRediT authorship contribution statement

Jialin Li: Data curation, investigation, software, formal analysis, visualization, and writing ‒ original draft. Chenxin Sun: Data curation, visualization, and writing – original draft. Fengzhong Wang: Formal analysis, funding acquisition, and writing – review & editing. Bei Fan: Investigation, supervision, and writing – review & editing. Xue Bai: Methodology and writing – review & editing. Ziyang Wu: Methodology and writing – review & editing. Xin Shi: Visualization, formal analysis, and writing – review & editing. Bolin Fan: Formal analysis, supervision, and writing – review & editing. Xiang Zou: Conceptualization and supervision. Jing Sun: Conceptualization, supervision, writing – review & editing, and funding acquisition.

Declaration of competing interest

The authors declare that they have no conflict of interest, and they do not have any other interests that influence the results and discussion of this paper.

References

[1] Guo Y, Chen X, Gong P, et al. Advances in the mechanisms of polysaccharides in alleviating depression and its complications. Phytomedicine. 2023; 109: 154566.

[2] Figee M, Riva—Posse P, Choi KS, Bederson L, Mayberg HS, Kopell BH . Deep brain stimulation for depression. Neurotherapeutics. 2022; 19(4): 1229-1245.

[3] Kverno KS, Mangano E . Treatment—resistant depression: approaches to treatment. J Psychosoc Nurs Ment Health Serv. 2021; 59(9): 7-11.

[4] Touloumis C. The burden and the challenge of treatment—resistant depression. Psychiatriki. 2021; 32(suppl I): 11-14.

[5] Yrondi A, Javelot H, Nobile B, et al. French society for biological psychiatry and neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment—resistant depression: update 2024. Encephale. 2025; 51(1): 26-38.

[6] Neuteboom D, Zantvoord JB, Goya—Maldonado R, et al. Accelerated intermittent theta burst stimulation in major depressive disorder: a systematic review. Psychiatry Res. 2023; 327: 115429.

[7] Jha MK, Mathew SJ . Pharmacotherapies for treatment—resistant depression: how antipsychotics fit in the rapidly evolving therapeutic landscape. Am J Psychiatr. 2023; 180(3): 190-199.

[8] David DJ, Gourion D . Antidepressant and tolerance: determinants and management of major side effects. Encephale. 2016; 42(6): 553-561 [French].

[9] Rothmore J . Antidepressant—induced sexual dysfunction. Med J Aust. 2020; 212(7): 329-334.

[10] Macaluso M, Preskorn SH . Antidepressants: From Biogenic Amines to New Mechanisms of Action. Cham, Switzerland: Springer International Publishing; 2019.

[11] Lu Y, Yu X, Wang Z, et al. Microbiota—gut—brain axis: natural antidepressants molecular mechanism. Phytomedicine. 2024; 134: 156012.

[12] Xie H, Xie Z, Luan F, et al. Potential therapeutic effects of Chinese herbal medicine in postpartum depression: mechanisms and future directions. J Ethnopharmacol. 2024; 324: 117785.

[13] Xu Y, Zhang J, Yu L, et al. Engeletin alleviates depression—like phenotype by increasing synaptic plasticity via the BDNF—TrkB—mTORC1 signalling pathway. J Cell Mol Med. 2023; 27(23): 3928-3938.

[14] Zhou Y, Nan F, Zhang Q, et al. Natural products that alleviate depression: the putative role of autophagy. Pharmacol Ther. 2024; 264: 108731.

[15] Mao Q, Zhang H, Zhang Z, et al. Co—decoction of Lilii Bulbus and Radix rehmannia Recens and its key bioactive ingredient verbascoside inhibit neuroinflammation and intestinal permeability associated with chronic stress—induced depression via the gut microbiota—brain axis . Phytomedicine. 2024; 129: 155510.

[16] Lyu S, Zhang G, Lu Y, et al. Pharmacological mechanism of natural antidepressants: the role of mitochondrial quality control. Phytomedicine. 2024; 129: 155669.

[17] Jiang N, Zhang Y, Yao C, et al. Hemerocallis citrina Baroni ameliorates chronic sleep deprivation—induced cognitive deficits and depressive—like behaviours in mice . Life Sci Space Res. 2024; 40: 35-43.

[18] Chen W, Kang S, Zhao D, et al. Study on prevention and treatment of depressive disorder by different Chinese herbal compounds from traditional Chinese medicine syndrome differentiation. Tradit Chin Drug Res Clin Pharmacol. 2025; 36(3): 479-488 [Chinese].

[19] Tang YQ, Li ZR, Zhang SZ, Mi P, Chen DY, Feng XZ . Venlafaxine plus melatonin ameliorate reserpine—induced depression—like behavior in zebrafish. Neurotoxicol Teratol. 2019; 76: 106835.

[20] Zhang L, Zhao XL, Cao ZJ, et al. Ginsenoside CK inhibits EMT and overcomes oxaliplatin resistance in gastric cancer by targeting the PI3K/Akt pathway. Phytomedicine. 2025; 140: 156516.

[21] Bai Y, Niu L, Song L, et al. Uncovering the effect and mechanism of Jiawei Xiaoyao wan in treating breast cancer complicated with depression based on network pharmacology and experimental analysis. Phytomedicine. 2024; 128: 155427.

[22] Xiao S, Liu L, Qin X, Xu L, Chai Z, Li Z . Cycloastragenol targets Fpr2 to inhibit the TLR4/NF—κB signaling pathway and alleviate neuroinflammation in Parkinson’s disease. Phytomedicine. 2025; 139: 156462.

[23] Song N, Wang Q, Bai Y, Fan L, Lan Y, Zhu X . Clinical application and dosage of Herba Menthae. Jilin J Chin Med. 2020; 40(9): 1225-1227 [Chinese].

[24] Ying L, Zheng H, Zhu J, Liang X, Liu H, Cui W . A new mouse model of depression induced by chronic restraint stress combined with lipopolysaccharide. J Psychiatr Res. 2024; 175: 96-102.

[25] Lu J, Xu X, Huang Y, et al. Prevalence of depressive disorders and treatment in China: a cross—sectional epidemiological study. Lancet Psychiatry. 2021; 8(11): 981-990.

[26] Zhao L, Zhang H, Li N, et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J Ethnopharmacol. 2023; 309: 116306.

[27] Liu X, Zheng X, Du G, Li Z, Qin X . Brain metabonomics study of the antidepressant—like effect of Xiaoyaosan on the CUMS—depression rats by¹H NMR analysis . J Ethnopharmacol. 2019; 235: 141-154.

[28] Su Z, Ruan J, Liu X, et al. Combining¹H—NMR—based metabonomics and network pharmacology to dissect the mechanism of antidepression effect of Milletia speciosa Champ on mouse with chronic unpredictable mild stress—induced depression . J Pharm Pharmacol. 2021; 73(7): 881-892.

[29] Xia Z, Zhang C, Du Y, et al. The effect of traditional Chinese medicine Zhikehoupu herbal pair on depressive behaviors and hippocampal serotonin 1A receptors in rats after chronic unpredictable mild stress. Psychosom Med. 2019; 81(1): 100-109.

[30] Zhu YL, Li SL, Zhu CY, Wang W, Zuo WF, Qiu XJ . Metabolomics analysis of the antidepressant prescription Danzhi Xiaoyao powder in a rat model of chronic unpredictable mild stress (CUMS). J Ethnopharmacol. 2020; 260: 112832.

[31] Mrinalini R, Tamilanban T, Naveen Kumar V, Manasa K . Zebrafish — the neurobehavioural model in trend. Neuroscience. 2023; 520: 95-118.

[32] Kaliya—Perumal AK, Ingham PW . Musculoskeletal regeneration: a zebrafish perspective. Biochimie. 2022; 196: 171-181.

[33] Li X, Liu Z, Liao J, Chen Q, Lu X, Fan X . Network pharmacology approaches for research of traditional Chinese medicines. Chin J Nat Med. 2023; 21(5): 323-332.

[34] Bai X, Bian Z, Zhang M . Targeting the Nrf2 signaling pathway using phytochemical ingredients: a novel therapeutic road map to combat neurodegenerative diseases. Phytomedicine. 2023; 109: 154582.

[35] Beurel E, Toups M, Nemeroff CB . The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020; 107(2): 234-256.

[36] Wróbel—Biedrawa D, Podolak I . Anti—neuroinflammatory effects of adaptogens: a mini—review. Molecules. 2024; 29(4): 866.

[37] Cai L, Gong Q, Qi L, et al. ACT001 attenuates microglia—mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway. Cell Commun Signal. 2022; 20(1): 56.

[38] Lei P, Li Z, Hua Q, et al. Ursolic acid alleviates neuroinflammation after intracerebral hemorrhage by mediating microglial pyroptosis via the NF—κB/NLRP3/GSDMD pathway. Int J Mol Sci. 2023; 24(19): 14771.

[39] Wu J, Han Y, Xu H, et al. Deficient chaperone—mediated autophagy facilitates LPS—induced microglial activation via regulation of the p300/NF—κB/NLRP3 pathway. Sci Adv. 2023; 9(40): eadi8343.

[40] Chen J, Lei C, Li X, et al. Research progress on classical traditional Chinese medicine formula Xiaoyaosan in the treatment of depression. Front Pharmacol. 2022; 13: 925514.

[41] Fan Q, Liu Y, Sheng L, et al. Chaihu—Shugan—San inhibits neuroinflammation in the treatment of post—stroke depression through the JAK/STAT3—GSK3β/PTEN/Akt pathway. Biomed Pharmacother. 2023; 160: 114385.

[42] Liu BH, Tu Y, Ni GX, et al. Total flavones of Abelmoschus manihot ameliorates podocyte pyroptosis and injury in high glucose conditions by targeting METTL3—dependent m ⁶A modification—mediated NLRP3—inflammasome activation and PTEN/PI3K/Akt signaling . Front Pharmacol. 2021; 12: 667644.

[43] Park S, Kim YS, Kim DY, So I, Jeon JH . PI3K pathway in prostate cancer: all resistant roads lead to PI3K. Biochim Biophys Acta Rev Cancer. 2018; 1870(2): 198-206.

[44] Savova MS, Mihaylova LV, Tews D, Wabitsch M, Georgiev MI . Targeting PI3K/AKT signaling pathway in obesity. Biomed Pharmacother. 2023; 159: 114244.

[45] Wang H, Gao L, Zhao C, et al. The role of PI3K/Akt signaling pathway in chronic kidney disease. Int Urol Nephrol. 2024; 56(8): 2623-2633.

[46] Du Y, Zhou L, Wen Z, Feng L, Zhang S, Zhang T . Slit2 suppresses endotoxin—induced uveitis by inhibiting the PI3K/akt/IKK/NF—κB pathway. Scand J Immunol. 2023; 98(6): e13319.

[47] Wu Y, Zhu Z, Lan T, et al. Levomilnacipran improves lipopolysaccharide—induced dysregulation of synaptic plasticity and depression—like behaviors via activating BDNF/TrkB mediated PI3K/Akt/mTOR signaling pathway. Mol Neurobiol. 2024; 61(7): 4102-4115.

[48] Zeng J, Xie Z, Chen L, et al. Rosmarinic acid alleviate CORT—induced depressive—like behavior by promoting neurogenesis and regulating BDNF/TrkB/PI3K signaling axis. Biomed Pharmacother. 2024; 170: 115994.

[49] Zheng Q, Liu L, Liu H, et al. The Bushen Yisui formula promotes axonal regeneration via regulating the neurotrophic factor BDNF/TrkB and the downstream PI3K/Akt signaling pathway. Front Pharmacol. 2019; 10: 796.

[50] Kritzer MD, Peterchev AV, Camprodon JA . Electroconvulsive therapy: mechanisms of action, clinical considerations, and future directions. Harv Rev Psychiatr. 2023; 31(3): 101-113.

[51] Li J, Zhang X, Guo D, et al. The mechanism of action of paeoniae radix rubra—Angelicae sinensis radix drug pair in the treatment of rheumatoid arthritis through PI3K/AKT/NF—κB signaling pathway. Front Pharmacol. 2023; 14: 1113810.